Enhanced DPP-GLB to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.

Sponsor
Lovoria Williams (Other)
Overall Status
Recruiting
CT.gov ID
NCT04757519
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
500
11
2
52.3
45.5
0.9

Study Details

Study Description

Brief Summary

This study seeks to establish the efficacy of identifying weight loss nonresponders early in a Diabetes Prevention Program (DPP) intervention in 20 community settings (primarily churches and community centers) and providing them with individual-level, enhanced treatment through telephone contacts and access to additional resources. Additionally, potential mediators and moderators of the relationship between intervention status and weight loss response at 6 months in both nonresponders and responders will be examined and a cost-effectiveness analysis to evaluate the cost of the intervention will be conducted.

This study addresses key gaps in the literature about the weight loss effects of identifying nonresponders early and characterizing individuals who need more intense personalized strategies. The investigators hypothesize that changes between baseline and 3 months will be more pronounced among the nonresponders in the intervention group compared to the nonresponders in the active control group.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: DPP-GLB Standard
  • Behavioral: DPP-GLB Enhanced
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Enhancing the Diabetes Prevention Program to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.
Actual Study Start Date :
Feb 18, 2021
Anticipated Primary Completion Date :
Jan 30, 2025
Anticipated Study Completion Date :
Jun 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: DPP-GLB Standard

Participants in this group will receive the standard Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.

Behavioral: DPP-GLB Standard
The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.

Experimental: DPP-GLB Enhanced

Participants in this group will receive the enhanced Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.

Behavioral: DPP-GLB Enhanced
The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.

Outcome Measures

Primary Outcome Measures

  1. Change in Weight at 12 Weeks [12 weeks (at baseline and12 weeks)]

    Weight will be measured in pounds using a cellular scale at baseline and at 12 weeks.

  2. Change in Weight at 6 Months [6 months (at baseline and 6 months)]

    Weight will be measured in pounds using a cellular scale at baseline and at 6 months.

Secondary Outcome Measures

  1. Change in Blood Pressure at 12 Weeks [12 weeks (at baseline and 12 weeks)]

    Blood pressure will be measured with calibrated automated blood pressure monitor at baseline and at 12 weeks.

  2. Change in Blood Pressure at 6 Months [6 months (at baseline and 6 months)]

    Blood pressure will be measured with calibrated automated blood pressure monitor at baseline and at 6 months.

  3. Change in Physical Activity at 12 Weeks [12 weeks (at baseline and 12 weeks)]

    Change in Physical Activity will be measured at baseline and 12 weeks using the Modifiable Activity Questionnaire (MAQ), which assesses activity frequency and duration. Scoring is open-ended; higher scores indicate increased activity.

  4. Change in Physical Activity at 6 Months [6 months (at baseline and 6 months)]

    Change in Physical Activity will be measured at baseline and 6 months using the Modifiable Activity Questionnaire (MAQ), which assesses activity frequency and duration. Scoring is open-ended; higher scores indicate increased activity.

  5. Change in Dietary Intake at 12 Weeks [12 weeks (at baseline and 12 weeks)]

    Change in Dietary Intake will be measured using the validated, Dana Farber eating habits tool and the Dietary screener questionnaire which assesses the frequency of consumption of selected foods and drinks. The scoring range of the survey is Never or less than once per month, 1-3 per month, 1 per week, 2-4 per week, 5-6 per week, 1 per day, 2-3 per day, 4-5 per day, 6 or more per day, Prefer not to answer. Higher scores indicated increased dietary intake.

  6. Change in Dietary Intake at 6 Months [6 months (at baseline, 12 weeks, 6 months)]

    Change in Dietary Intake will be measured using the validated, Dana Farber eating habits tool and the Dietary screener questionnaire which assesses the frequency of consumption of selected foods and drinks. The scoring range of the survey is Never or less than once per month, 1-3 per month, 1 per week, 2-4 per week, 5-6 per week, 1 per day, 2-3 per day, 4-5 per day, 6 or more per day, Prefer not to answer. Higher scores indicated increased dietary intake.

  7. Cost Analysis [6 months]

    Investigator-developed instrument. At 6 months, conduct a cost-effectiveness analysis to evaluate the cost of the intervention arm by comparing the incremental cost and weight loss with the active control arm.

  8. Impact of Weight on Quality of Life [6 months]

    Quality of life will be measured using Impact of Weight on Quality of Life Questionnaire (IWQOL-Lite). This is a 31-item self-report scale. Scores range from 0-100; higher scores indicate greater quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • self-described as Black

  • non-diabetic

  • body mass index (BMI) equal to or greater than 25

  • CDC diabetes risk assessment greater than or equal to 5 or diabetes pre-diagnosis or history of gestational diabetes

  • live within driving distance of participating church/site

Exclusion Criteria:
  • diagnosed Type 1 or 2 diabetes

  • pregnant or planning to become pregnant during study period

  • contraindications to moderate physical activity

  • serious medical condition that contradicts weight loss

  • not Black or African American

Contacts and Locations

Locations

Site City State Country Postal Code
1 Consolidated Baptist Church Lexington Kentucky United States 40505
2 Historic St. Paul AME Church Lexington Kentucky United States 40507
3 First African Baptist Church Lexington Kentucky United States 40508
4 Pilgrim Baptist Church Lexington Kentucky United States 40508
5 Shiloh Baptist Church Lexington Kentucky United States 40508
6 First Baptist Church Brackstown Lexington Kentucky United States 40511
7 Lima Drive Seventh Day Adventist Church Lexington Kentucky United States 40511
8 Bates Memorial Baptist Church Louisville Kentucky United States 40203
9 St. Stephen Baptist Church Louisville Kentucky United States 40210
10 Forest Baptist Church Louisville Kentucky United States 40218
11 First Baptist Winchester Winchester Kentucky United States 40391

Sponsors and Collaborators

  • Lovoria Williams
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

  • Principal Investigator: Lovoria Williams, University of Kentucky

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lovoria Williams, Associate Professor, University of Kentucky
ClinicalTrials.gov Identifier:
NCT04757519
Other Study ID Numbers:
  • 58766
  • 1R01DK125801-01
First Posted:
Feb 17, 2021
Last Update Posted:
Jun 14, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lovoria Williams, Associate Professor, University of Kentucky
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 14, 2022